Skip to main content

Table 1 Patient characteristics and clinical outcomes

From: Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer

Number of patients

42

Age (years)

 

 Mean

63.1

 Range

37-81

Sex

 

 Males

21

 Females

21

Stage

 

 III

14

 IV

19

 Recurrence

9

Liver metastasis (pretreatment)

 

 Absence

35

 Presence

7

HLA

 

 HLA-A24

24

 Others

17

 Unknown

1

Administration (times)

 

 < 3

22

 ≧ 3

20

Number of CTLs (×108/time)

 

 Mean

6.3

 Range

1.0-12.4

Number of DCs (×107/time)

 

 Mean

1.8

 Range

0.04-3.9

Prior therapy

 

 None

25

 Tumor resection

9

 Chemotherapy

16

 Radiotherapy

0

Response

 

 CR

1

 PR

3

 SD

22

 PD

16

  1. HLA; human leukocyte antigen, CTL; cytotoxic T lymphocyte,DC; dendritic cell, CR; complete response, PR; partial response,SD; stable disease, PD; progressive disease.